Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Claudio VernieriFederico NichettiLuca LalliLuca MoscettiCarlo Alberto GiorgiGaia GriguoloAntonio MarraGiovanni RandonCarmen G ReaFrancesca LigorioSimone ScagnoliClaudia De AngelisChiara MolinelliAgnese FabbriEmanuela FerraroDario TrapaniAndrea MilaniElisa AgostinettoOttavia BernocchiGiovanna CataniaAmelia VantaggiatoMichela PalleschiAnna MorettiDebora BasileMarika CinauseroArta AjaziLorenzo CastagnoliSalvatore Lo VulloLorenzo GerratanaFabio PuglisiNicla La VerdeGrazia ArpinoAndrea RoccaMariangela CiccareseRebecca PedersiniAlessandra FabiDaniele GeneraliAgnese LosurdoFilippo MontemurroCurigliano GiuseppeLucia Del MastroAndrea MichelottiEnrico CortesiValentina GuarneriGiancarlo PruneriLuigi MarianiFilippo de BraudPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The impact of on-treatment glycemia on the efficacy of everolimus-exemestane therapy in patients with HR+/HER2- aBC depends on baseline glycemia. This study lays the foundations for investigating novel therapeutic approaches to target the glucose/insulin axis in combination with PI3K/AKT/mTORC1 inhibitors in patients with HR+/HER2- aBC.